Liver Cirrhosis stem cell therapy — your questions answered (2026)
About stem cell therapy for Liver Cirrhosis
Cirrhosis is advanced liver scarring caused by different diseases and can lead to portal hypertension, infection, encephalopathy, cancer and liver failure. Cell proposals aim to influence inflammation or regeneration, but a laboratory mechanism does not show reversal of established fibrosis or restored liver function. Product source, processing, route and disease cause matter.
The evidence for Liver Cirrhosis
Cell studies remain investigational and heterogeneous; changes in laboratory values must not be equated with survival, fewer decompensations or avoidance of transplantation. The NIDDK cirrhosis treatment guide emphasises treating the cause and complications, surveillance and liver-transplant assessment for liver failure. Experimental access should occur only through a verified protocol without delaying those measures.
An itemised estimate should separate research product, admission, imaging, laboratory monitoring, treatment of ascites or infection, travel, follow-up and emergency or transplant care. Do not treat a commercial infusion price as an alternative to specialist hepatology and transplant planning.
Can stem cells repair the liver?
Cell therapy for Liver Cirrhosis may be offered as an individualised programme, but regulatory status depends on the product, processing, indication and jurisdiction. It is currently investigational. Verify authorisation status, cell source, release testing and clinical evidence for the specific proposal.
Which cirrhosis stage qualifies?
Schedules vary by the exact product, protocol, route, monitoring needs and clinical context. Request the proposed schedule and its evidence before making travel arrangements.
What improvement is realistic?
Eligibility depends on the protocol's inclusion and exclusion criteria and an appropriately qualified clinician's assessment. An online checklist cannot determine candidacy or replace medical advice.
Cost in the EU?
The partner-published indicative range for an Liver Cirrhosis programme is €3,000–€8,000 for treatment. Request a current written quotation and compare product, dose, visits, inclusions and follow-up before using country ranges as a benchmark.
Sources & further reading
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
- Open clinical trials for Liver Cirrhosis (ClinicalTrials.gov) ↗
- Peer-reviewed research on PubMed ↗
- ISSCR patient guide — what to ask ↗
- FDA consumer warning on stem-cell therapies ↗
- EMA — advanced-therapy (ATMP) framework ↗
- Clinic perspective — Stem Plus on Liver Cirrhosis ↗